Pataki has announced that 14 community-based organizations in New York State have already been awarded grants totaling $700,000 to help prevent or control diabetes among New Yorkers. ‘Keeping New Yorker’s healthy and assisting them in living lengthy, healthy lives is a priority and that is why we’ve worked so hard to make our health care system among the best in the country,’ Governor Pataki said. ‘Diabetes is a significant public health problem that is best dealt with through early recognition, self-management and education which statewide initiative builds on our dedication to increasing public consciousness about diabetes and educating families on how best to detect and manage this disease.’ Related StoriesStudy suggests dependence on specific treatment options for adolescents with onset type 2 diabetesDiabetes avoidance starts in the wombWeight-loss surgery may be secure for managing type 2 diabetes in patients with gentle obesityThe partnerships getting awards today provides providers and support to communities that are most at risk for an increased prevalence of diabetes among New Yorkers.Further, ALN-AAT administration led to marked improvements in hepatocyte cellular morphology as assessed by electron microscopy. Finally, 98 percent suppression of liver mRNA and serum proteins was noticed 48 hours after an individual dose of the medication in transgenic mice that got fibrotic livers, illustrating key pre-clinical proof of concept for RNAi-mediated treatment in diseased livers. Alnylam in addition has identified a GalNAc-siRNA targeting AAT that enables subcutaneous dosage administration for further development. Related StoriesProtein sensor for proprioception foundNew Global International and Energy Sustainability Group consent to manufacture, distribute MoringaUP Protein BarsDiscovery could offer clues to how some viruses control expression of genetic material In addition, in a poster titled Liposome mediated delivery of siRNA to hepatic stellate cells, Alnylam scientists presented new data on the systemic delivery of RNAi therapeutics to quiescent and activated hepatic stellate cells .